RPG Life Sciences Q1 FY27: consolidated PAT up 17% YoY to ₹30.76 Cr as margins expand

RPG Life Sciences posted consolidated revenue from operations of ₹195.69 Cr for Q1 FY27 (quarter ended June 30, 2026), up 15.9% YoY (₹168.92 Cr) and 10.6% QoQ (₹176.89 Cr). Consolidated PAT came in at ₹30.76 Cr, up 17.0% YoY (₹26.29 Cr) and a more modest 2.9% QoQ (₹29.90 Cr) — the YoY print is the primary signal here since profit growth outpaced revenue growth, pointing to margin expansion rather than a one-off. Standalone tells an almost identical story (PAT ₹30.57 Cr, EPS ₹18.49 vs consolidated EPS ₹18.60), so the small consolidation delta from the newly formed subsidiary RPG Active Pharma Limited is not yet material to the group numbers.

On margins, operating profitability (EBITDA/revenue) improved to roughly 22.1% from ~21.0% a year ago and ~19.2% last quarter, while the net margin held broadly flat at 15.35% (15.1% YoY, 15.8% QoQ) as tax incidence normalised (effective tax rate ~25.8% this quarter vs ~25.8% YoY). Cost of materials consumed (₹37.68 Cr) and employee benefits expense (₹37.76 Cr) grew slower than revenue, the main driver of the operating-margin gain; finance costs rose sharply in percentage terms (₹0.63 Cr vs ₹0.13 Cr YoY) though off a small base, likely tied to working-capital or subsidiary-related funding.

The stock went into the print at ₹2,888.7, up 26.6% over the past month of trading.

For context: PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.

No exceptional items this quarter or year-ago quarter, unlike Q4 FY26 which carried insurance-settlement income and one-off write-offs — a clean like-for-like comparison

There is no consensus or brokerage estimate on record for this stock — it carries no visible formal analyst coverage, so vsStreet is unknown rather than a miss/beat call. Similarly, the company has issued no formal forward guidance in our records or in a web search, so the quarter cannot be graded against a stated management target; management's own press commentary on this result had not been separately released as of this filing. Corporate context this quarter includes the Board approving the unaudited Q1 results on July 28, 2026, the 19th AGM held July 23, 2026, a BRSR sustainability filing, and a July 13, 2026 tie-up with Archerchem to launch Naprosyn ES in India — a new-launch item that is a forward revenue lever rather than a driver of this quarter's print. The Board's December 2025 approval to transfer the API division into wholly-owned subsidiary RPG Active Pharma Limited remains pending regulatory sign-off and is the main structural item to track into subsequent quarters, since it will reshape the standalone/consolidated split once completed.